ThRombosis ExclUsion STudy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

5935 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-25

Study Completion Date

2024-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.

Secondary objectives:

1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV)
2. To constitute a plasma bank to be used for future studies with other DDi assays under development by Stago.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis

NCT02078154

Deep Venous Thrombosis

TERMINATED

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

NCT00720915

Deep Vein Thrombosis Pulmonary Embolism

COMPLETED NA

A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay

NCT04737954

Deep Vein Thrombosis Pulmonary Embolism Venous Thromboembolism

UNKNOWN NA

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

NCT02596555

Pulmonary Embolism

TERMINATED PHASE4

Below Knee DVT Study

NCT03805672

Deep Vein Thrombosis (DVT) Blood Clots

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population will be selected from prospective, consecutive ambulatory outpatients suspected of having venous thromboembolism. Patients will be diagnosed for VTE (PE or DVT) based on local standard of care. Samples will be collected (additional blood draw or additional volume during blood draw) for future testing with new D-Dimer assay.

In case of Low/Moderate PTP score and negative VTE diagnosis, patients will be followed for 3 months to evaluate potential development of deep venous thrombosis and/or pulmonary embolism.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deep Venous Thromboses Pulmonary Embolism Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Embolism (PE)

Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.

Enrolment completed for this group : 13th February 2020

DDimer test

Intervention Type DIAGNOSTIC_TEST

Measuring the level of DDimer in blood sample

Deep Venous Thrombosis (DVT)

Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.

Enrolment completed for this group : 29th March 2023

DDimer test

Intervention Type DIAGNOSTIC_TEST

Measuring the level of DDimer in blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DDimer test

Measuring the level of DDimer in blood sample

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is \< 80 years old.
2. Patient presents at least one of these symptoms indicative of proximal DVT or PE:

* symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,
* symptoms for PE: hemoptysis, lung related chest pain, dyspnea.
3. Patient provides written informed consent to participate in the study
4. Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone.

Exclusion Criteria

1. Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:

* Fibrinolytic therapy within the previous seven (7) days,
* Disseminated intravascular coagulation
* Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,
* Deep hematoma diagnosed by imaging techniques within the previous one (1) month,
* Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),
* Sepsis, severe infections, pneumonia within the previous 1 month,
* Known liver cirrhosis,
* Pregnancy or having delivered within the previous 1 month,
* Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),
* Sickle cell disease,
2. Patients presenting with a suspect thrombotic event related to catheter implantation
3. Ongoing therapeutic anticoagulants (curative and preventive regimen) started twenty four (24) hours or more before blood draw (except aspirin and platelet inhibitors)
4. Previous anticoagulant therapy stopped less than three (3) months before blood draw (except aspirin and platelet inhibitors)
5. Patients with previous DVT/PE occurred less than three (3) months from screening.
6. Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)
7. Patients with known tissue plasminogen activator (tPA) deficiency
8. Patient participating or who has participated within one month of enrolment in another investigational study
9. Major co-morbid condition(s) or other reasons that could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No